Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors (Q39226360)
Jump to navigation
Jump to search
scientific article published on 21 March 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors |
scientific article published on 21 March 2014 |
Statements
1 reference
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors (English)
1 reference
Jordi Rodon
1 reference
Irene Braña
1 reference
Lillian L Siu
1 reference
Maja J De Jonge
1 reference
Natasha Homji
1 reference
David Mills
1 reference
Emmanuelle Di Tomaso
1 reference
Celine Sarr
1 reference
Lucia Trandafir
1 reference
Cristian Massacesi
1 reference
Ferry Eskens
1 reference
Johanna C Bendell
1 reference
21 March 2014
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference